Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week. Parkinson’s disease ...

US-based pharmaceutical company AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon, its D1/D5 partial agonist candidate for early-stage Parkinson's disease, met its primary endpoint.

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a ...

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

The North Chicago, Ill.-based biotech said a third Phase 3 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease met its primary and secondary endpoints ...

Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

Symptoms of Parkinson’s disease, such as tremors and stiffness, can make daily tasks difficult. A new drug has shown promise in alleviating symptoms. Tavapadon, a drug being tested to treat ...